| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | 4.3 | 3.9 |
| Gross profit | 3.6 | 3.2 |
| Profit before tax | -0.8 | -0.7 |
| Net income | -0.8 | -0.7 |
| EPS (diluted, $ a share) | $-0.05 | $-0.03 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +11.5% |
|---|---|
| Gross margin | 83.3% |
| Operating margin | 7.8% |
10-Q filed with the SEC, OTC: BTCY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Biotricity Inc.: key numbers
- Share price
- $0.0521Close, Nov 16
- Market cap
- $1.13M
- Shares outstanding
- 21.63MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Biotricity Inc.
All →Biotricity Leadership Change
Jainal Bhuiyan resigned as a member of the Board of Directors and the Compensation Committee of Biotricity Inc., effective September 22, 2026. The company stated the resignation was not due to any disagreement, and Ronald McClurg was appointed to fill the vacancy on the Compensation Committee.